China Double CRA: Trading Snapshot and Regulatory Milestone

The Shanghai‑listed stock China Double CRA (600062.SS) closed the trading day on Wednesday, 21 October 2026, without any change in price, remaining flat at CNY 16.11. Over the 24‑hour period ending at 18:44 PM Central Europe, the shares were traded for a total of CNY 131.1 million, representing a modest volume relative to the market‑cap of CNY 16.8 billion and the available supply of 1 billion shares.

The 200‑day simple moving average sits at CNY 16.43, indicating that the current price is slightly below the medium‑term trend. Over the last 52 weeks, the share experienced a high of CNY 19.77 on 12 November 2025 and a low of CNY 15.29 on 29 June 2026, underscoring a relatively narrow range of volatility.

Regulatory Update: Beijing Wanhui Double Crane Pharmaceutical Ltd.

In a development that may enhance the company’s earnings prospects, China Resources Double CRA has announced that its wholly‑owned subsidiary, Beijing Wanhui Double Crane Pharmaceutical Ltd., has been granted a drug registration certificate for an oral tablet formulation of Baricitinib by the National Medical Products Administration (NMPA).

Baricitinib, a Janus kinase inhibitor, is indicated for the treatment of rheumatoid arthritis and related inflammatory conditions. The NMPA’s approval confirms the product’s classification as a Class 4 chemical medicine and verifies that it meets the required safety and efficacy standards. The certification is expected to provide a solid foundation for the subsidiary’s commercial activities and could potentially broaden the parent company’s pharmaceutical portfolio.

While China Double CRA traded flat, other stocks listed on the Shanghai and Shenzhen exchanges exhibited similar stability in the last 24 hours:

  • Jianshe Industry Yun (002265.SZ) – CNY 19.39, market cap CNY 20.2 bn, P/E 78.13.
  • Shanghai M&g Stationery (603899.SS) – CNY 21.76, market cap CNY 20.1 bn, P/E 15.28.
  • Wuhan Dameng Database L (688692.SS) – CNY 178, market cap CNY 20.1 bn.
  • Chengdu Xuguang Electronic (600353.SS) – CNY 24.29, market cap CNY 20.2 bn, P/E 117.4.
  • Jilin Aodong Pharmaceutical (000623.SZ) – CNY 17.03, market cap CNY 20.2 bn, P/E 6.31.

Across the broader market, the Shanghai Composite Index slipped marginally, whereas the Shenzhen component and the ChiNext index posted modest gains. Trading volume for the day reached approximately 934 billion yuan. Technology sectors such as smart‑speaker, Wi‑Fi 6, and wireless‑earbud themes performed well, while defense‑related groups, including China Shipbuilding and certain armament restructuring names, experienced declines. Battery‑cell producers dominated turnover, with other large‑cap technology firms following suit. The morning session saw 395 shares advance against 1,507 that fell.

Company Overview

China Resources Double‑Crane Pharmaceutical Co., Ltd. is headquartered in Beijing and operates within the healthcare sector, focusing on the development, manufacturing, and marketing of a variety of medical products, including anti‑influenza agents, antihypertensives, and antibiotics. The company is listed on the Shanghai Stock Exchange, with its initial public offering dating back to 6 May 1997. Further information about its product line and corporate activities can be found on the company’s website, www.dcpc.com .